More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Paclitaxel [33069-62-4]
Chemical Structure
Chemical Structure
Chemical Structure

Paclitaxel [33069-62-4]

Research Use Only
AG-CN2-0045
AdipoGen Life Sciences
CAS Number33069-62-4
DownloadMSDS
Product group Chemicals
Estimated Purity>99%
Molecular Weight853.9
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Paclitaxel
  • Delivery Days Customer
    10
  • CAS Number
    33069-62-4
  • Certification
    Research Use Only
  • Estimated Purity
    >99%
  • Hazard Information
    Danger
  • Molecular Formula
    C47H51NO14
  • Molecular Weight
    853.9
  • Scientific Description
    Anticancer compound [1, 11, 14]. Chemotherapeutic used in patients with cancer and advanced forms of Kaposis sarcoma [11, 12]. Microtubule assembly stabilizer. Reversibly binds to polymerized tubulin [2, 3, 6, 13, 14]. Anti-mitotic. Mitotic spindle assembly, chromosome segregation and cell division inhibitor. Induces cell cycle arrest at the G2/M phase [4, 5, 10, 13]. Apoptosis inducer through aberrant activation of cyclin-dependent kinases (CKDs) and the c-Jun N-terminal kinase/stress activated protein kinase (JNK/SAPK) [7-9, 10]. Immunosuppressor. Immunostimulant [15]. Antiproliferative agent for the prevention of restenosis [16]. TRAIL sensitizer [17] - Chemical. CAS: 33069-62-4. Formula: C47H51NO14. MW: 853.9. Isolated from the bark of the pacific yew tree (Taxus brevifolia). Anticancer compound. Chemotherapeutic used in patients with cancer and advanced forms of Kaposis sarcoma. Microtubule assembly stabilizer. Reversibly binds to polymerized tubulin. Anti-mitotic. Mitotic spindle assembly, chromosome segregation and cell division inhibitor. Induces cell cycle arrest at the G2/M phase. Apoptosis inducer through aberrant activation of cyclin-dependent kinases (CKDs) and the c-Jun N-terminal kinase/stress activated protein kinase (JNK/SAPK). Immunosuppressor. Immunostimulant. Antiproliferative agent for the prevention of restenosis. TRAIL sensitizer
  • SMILES
    [H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352200

References

  • Cytotoxic studies of paclitaxel (Taxol®) in human tumour cell lines: J.E. Liebmann, et al.; Br. J. Cancer 68, 1104 (1993)
  • Taxol (paclitaxel): mechanisms of action: S.B. Horwitz; Ann. Oncol. 5, S3 (1994) (Review)
  • Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity: R. Foa, et al.; Int. J. Clin. Lab. Res. 24, 6 (1994) (Review)
  • Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway: C.M. Woods, et al.; Mol. Med. 1, 506 (1995)
  • Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle: A. Jordan, et al.; Med. Res. Rev. 18, 259 (1998)
  • How Taxol stabilises microtubule structure: L.A. Amos & J. Löwe; Chem. Biol. 6, R65 (1999) (Review)
  • Mechanisms of Taxol-induced cell death are concentration dependent: K. Torres & S.B. Horwitz; Cancer Res. 58, 3620 (1998)
  • Molecular effects of paclitaxel: myths and reality (a critical review): M.V. Blagosklonny & T. Fojo; Int. J. Cancer 83, 151 (1999)
  • Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK) dependent and -independent pathways in ovarian cancer cells: T.H. Wang, et al.; J. Biol. Chem. 274, 8208 (1999)
  • Paclitaxel-induced cell death: where the cell cycle and apoptosis come together: T.H. Wang, et al.; Cancer 88, 2619 (2000)